Physician profile
Joel Camilo
NPI 1144234733
$11,181.67
in general payments reported to CMS, 2019-2025
39 companies · $2,644 in 2025
The $2,644 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $1,274 · 2021: $840 · 2022: $1,882 · 2023: $1,611 · 2024: $1,881 · 2025: $2,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,116 · Education: $19.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,115.88 |
| Education | $19.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,985.39 | 2019-2025 | Rinvoq, Creon, Skyrizi |
| Boston Scientific Corporation | $1,390.97 | 2020-2025 | Exalt Model D |
| Takeda Pharmaceuticals U.S.A., INC. | $742.23 | 2019-2025 | Entyvio, Eohilia |
| Medtronic, INC. | $645.58 | 2023-2025 | Gi Genius, Nexpowder, Endoflip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $553.46 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $534.67 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $397.18 | 2021-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $347.71 | 2022-2025 | Epclusa, Livdelzi |
| Intercept Pharmaceuticals, INC. | $289.18 | 2022-2025 | Ocaliva |
| Genzyme Corporation | $283.20 | 2021-2025 | |
| Pfizer INC. | $240.39 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $225.00 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $188.92 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $181.43 | 2025 | Iqirvo |
| Ardelyx, INC. | $173.24 | 2024-2025 | Ibsrela |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $169.90 | 2023-2025 | Sucraid |
| Allergan, INC. | $158.10 | 2019 | |
| Merck Sharp & Dohme LLC | $148.61 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $141.06 | 2023-2025 | Terlivaz |
| Conmed Corporation | $139.58 | 2025 | Conmed Biliary, Conmed Hemostasis |
| Madrigal Pharmaceuticals | $131.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $130.49 | 2021-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $126.14 | 2024-2025 | Zenpep |
| Portola Pharmaceuticals, LLC | $120.72 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $101.65 | 2022 | |
| Vivus LLC | $97.51 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $94.01 | 2021-2024 | Linzess |
| Redhill Biopharma INC. | $78.75 | 2020-2022 | |
| Lilly USA, LLC | $69.73 | 2025 | Omvoh |
| Organon LLC | $58.05 | 2024-2025 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $42.92 | 2022 | |
| Celltrion USA INC. | $39.04 | 2023-2025 | Yuflyma, Vegzelma |
| Olympus America INC. | $28.87 | 2021-2025 | |
| Amgen INC. | $27.14 | 2022 | |
| Novo Nordisk INC | $23.05 | 2025 | Wegovy |
| Covidien LP | $20.48 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $20.13 | 2019 | |
| Endo Pharmaceuticals INC. | $19.45 | 2019 | |
| Digestive Care, INC. | $16.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Camilo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.